



Press Release

BMBF grant awarded to AMP Therapeutics

Leipzig (Germany), October 9, 2012 – FOR IMMEDIATE RELEASE

AMP Therapeutics GmbH (AMPT), a company developing novel antibiotic therapies, announced today the successful acquisition of non-dilutive funding from Germany's Federal Ministry for Education and Research (BMBF).

In a joint application with Prof. Ralf Hoffmann's group at the University of Leipzig the consortium was awarded a total grant volume of more than € 1.8 mil.

The funding will take the form of a non-repayable reimbursement of specific development costs expended by AMPT until September 2014. The total cost of this development program is estimated to be € 2.2 mil of which the BMBF committed to provide up to € 1.8 mil in funding within its Innovative Therapies program.

"The ATA type of antimicrobial peptides is an exciting compound class with the potential to treat a broad range of medical conditions caused by Gram-negative pathogens. We are pleased that the BMBF recognizes the potential of this novel approach to treat bacterial infections and has chosen to support with AMPT" said Knut Adermann, Managing Director responsible for Research and Development at AMPT.

"We are very pleased to expand our existing partnership with the University of Leipzig by securing this BMBF funding together that will allow us to continue with the development of our technology and lead candidates," said Dr. Marc W. Hentz, Managing Director responsible for Finances and Business Development. "The validation of our technology by the BMBF further underscores the commitment made by our existing investors Boehringer Ingelheim Venture Fund and Novartis Venture Funds."

Proceeds from the financing will be used to advance AMPT's Gram-negative antibiotic program. More specifically the pharmacological and toxicological profile of ATA peptides derived from insects will be defined in more detail to accelerate the development of AMPT's product pipeline.

About AMP Therapeutics (AMPT)

AMP Therapeutics was founded in 2009 as a spin-off from Prof. Ralf Hoffmann's laboratory at the University of Leipzig and is based at the BIO CITY in Leipzig, Germany. AMPT is engaged in the discovery and commercialization of new medicines for the treatment of severe bacterial infections predominantly caused by drug-resistant Gram-negative bacteria. Infections caused by drug-resistant pneumonia, bloodstream infections, surgical site infections and urinary tract infections represent a major global health threat with an unfavorable prognosis and are largely untreatable with existing antibiotics. AMPT addresses this significant unmet medical need by advancing the preclinical and clinical development of its proprietary antibacterial compounds. AMPT's technology is based on naturally occurring antimicrobial peptides found across various species. Investors in AMP Therapeutics GmbH are Boehringer Ingelheim Venture Fund and Novartis Venture Funds.

www.amp-therapeutics.com

Contact: Dr. Marc W. Hentz, Managing Director AMP-Therapeutics GmbH

info@amp-therapeutics.com